drugset / Trial / NCT01030120

Etanercept for the Treatment of Chronic Urticaria

NCT01030120

Phase 2/3 Withdrawn University of Utah
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of etanercept for patients with chronic idiopathic urticaria unresponsive to antihistamines.

Timeline

Start
2010-12
Primary completion
2012-07
Completion
2012-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etanercept Protein / enzyme biologic 50 mg Subcutaneous